9 research outputs found
Predictors for cerebral edema in acute ischemic stroke treated with intravenous thrombolysis
Cerebral edema (CED) is a severe complication of acute ischemic stroke. There is uncertainty regarding the predictors for the development of CED after cerebral infarction. We aimed to determine which baseline clinical and radiological parameters predict development of CED in patients treated with intravenous thrombolysis. We used an image-based classification of CED with 3 degrees of severity (less severe CED 1 and most severe CED 3) on postintravenous thrombolysis imaging scans. We extracted data from 42 187 patients recorded in the SITS International Register (Safe Implementation of Treatments in Stroke) during 2002 to 2011. We did univariate comparisons of baseline data between patients with or without CED. We used backward logistic regression to select a set of predictors for each CED severity. CED was detected in 9579/42 187 patients (22.7%: 12.5% CED 1, 4.9% CED 2, 5.3% CED 3). In patients with CED versus no CED, the baseline National Institutes of Health Stroke Scale score was higher (17 versus 10; P<0.001), signs of acute infarct was more common (27.9% versus 19.2%; P<0.001), hyperdense artery sign was more common (37.6% versus 14.6%; P<0.001), and blood glucose was higher (6.8 versus 6.4 mmol/L; P<0.001). Baseline National Institutes of Health Stroke Scale, hyperdense artery sign, blood glucose, impaired consciousness, and signs of acute infarct on imaging were independent predictors for all edema types. The most important baseline predictors for early CED are National Institutes of Health Stroke Scale, hyperdense artery sign, higher blood glucose, decreased level of consciousness, and signs of infarct at baseline. The findings can be used to improve selection and monitoring of patients for drug or surgical treatment
Characterization of human glutathione-dependent microsomal prostaglandin E synthase-1
Prostaglandins (PGs) are lipid mediators, which act as local hormones.
PGs are formed in most calls and are synthesized de novo from
membrane-released arachidonic acid (AA) upon cell activation.
Prostaglandin H synthase (PGHS) -1 or 2, also referred to as COX-1 and
COX-2, metabolize AA to PGH2, which is subsequently converted in a
cell-specific manner by downstream enzymes to biologically active
prostanoids, i.e. PGE2, PGD2, PGF2alpha, PGI2 or TXA2. PGHS-1 is
constitutively expressed in many calls and is mainly involved in
housekeeping functions, such as vascular homeostasis, whereas PGHS-2 can
be induced by proinflammatory cytokines at sites of inflammation.
Prostaglandin E synthase (PGES) specifically catalyzes the conversion of
PGH2 to PGE2, which is a biologically potent prostaglandin involved in
several pathological conditions; including pain, favor, inflammation and
possibly some forms of cancers and neurodegenerative diseases.
mPGES-1 was initially identified as a homologue to microsomal glutathione
transferase-1 (MGST1) with 37% identity on the amino acid sequence level
and referred to as MGST1-like 1 (MGST1-L1). Based on the properties of
MGST1-L1, regarding size, amino acid sequence, hydropathy and membrane
localization, the protein was identified as a member of the
MAPEG-superfamily (membrane-associated proteins in eicosanoid and
glutathione metabolism). The superfamily consists of 16- 18 kDa, integral
membrane proteins with typical hydropathy profiles and diverse functions.
The MAPEG family comprises six human members, which in addition to
mPGES-1 are; 5-lipoxygenase activating protein (FLAP), leukotriene C4
synthase (LTC4S), MGST1, MGST2 and MGST3. MGST1 -2 and -3 are glutathione
transferases as well as glutathione-dependent peroxidases, while FLAP and
LTC4S are crucial for leukotriene biosynthesis.
Human mPGES-1 was cloned and characterized as a 16 kDa, inducible
GSH-dependent microsomal PGE synthase. Northern dot blot analysis of
mPGES-1 mRNA demonstrated a low expression in most tissues, medium
expression in reproductive organs and a high expression in two cancer
cell lines (A549 and HeLa). A549 cells had been used earlier as a model
system to study PGHS-2 induction by the proinflammatory cytokine IL-1beta
and mPGES-1 was also induced by IL-1beta in these calls. A protein of
similar size was detected in microsomes from sheep vesicular glands,
which are known to contain a highly efficient microsomal PGES, indicating
that mPGES-1 was the long-sought membrane bound PGES. Furthermore, a time
study of PGHS-2 and mPGES-1 expression revealed a coordinate induction of
these enzymes, which was correlated with increased PGES activity in the
microsomal fraction. Tumor necrosis factor-alpha (TNF-alpha) also induced
mPGES-1 in these cells and dexamethasone was found to counteract the
effect of these cytokines on mPGES-1 induction. A method based on RP-HPLC
and UV-detection was developed to efficiently quantify PGES activity. A
small set of potential mPGES-1 inhibitors were tested and NS-398,
Sulindac sulfide and LTC4 were found to inhibit PGES activity with
IC50-values of 20 µm, 80 µm and 5 µm, respectively.
The human mPGES-1 gene structure was investigated. The mPGES-1 gene span
a region of approximately 15 kb, is divided into three exons, and is
localized on chromosome 9q34.3. A 682 bp fragment directly upstream of
the translation start site exhibited promoter activity when transfected
in A549 calls. The putative promoter is GC-rich, lacks a TATA box at a
functional site and contains numerous potential transcription factor
binding-sites. Two GC-boxes, two tandem Barble-boxes and an aryl
hydrocarbon response element were identified. The putative promoter
region of mPGES1 was transcriptionally active and reporter constructs
were regulated by IL-1beta and phenobarbital.
The expression of mPGES-1 was investigated in synovial tissues from
patients suffering from rheumatoid arthritis (RA). Primary synovial cells
obtained from patients with RA were treated with IL-1beta or TNF-alpha.
Both cytokines were found to induce mPGES-1 mRNA from low basal levels to
maximum levels after 24 hours and the induction by IL-1beta was inhibited
by dexamothasone in a dose-dependent manner. The protein expression of
mPGES-1 was also induced by IL-1beta with a linear increase up to 72 h.
In contrast, the PGHS-2 induction demonstrated an earlier peak expression
(4-8 h). Furthermore, the protein expression of mPGES-1 was correlated
with increased microsomal PGES activity. In these biochemical experiments
any significant contribution of cytosolic PGES or other cytosolic or
nonn-inducible membrane bound PGE syntheses was ruled out.
A purification protocol for mPGES-1 was developed. Human mPGES-1 was
expressed with a histidine tag in Eschericha coli, solubilized by Triton
X-100 and purified by a combination of hydroxyapatite and immobilized
metal affinity chromatography. mPGES-1 catalyzed a rapid GSH-dependent
conversion of PGH2 to PGE2 (170 µmol/min mg). The enzyme, also displayed
a high GSH-dependent activity against PGG2, forming 15hydroperoxy PGE2
(250 µmol/min mg). In addition, mPGES-1 possessed several other
activities; glutathionedependent peroxidase activity towards cumene
hydroperoxide, 5-HpETE and 15-hydroperoxy-PGE2, as well as conjugation of
1-chloro-2,4-dinitrobenzene (CDNB) to GSH. These activities likely
reflect the relationship with other MAPEG enzymes. Two-dimensional
crystals of purified mPGES-1 were obtained and a 10 A projection map was
determined by electron crystallography. Hydrodynamic studies were also
performed on the mPGES-1-Triton X-100 complex to investigate the
oligomeric state of the protein. Electron crystallography and
hydrodynamic studies independently demonstrated a trimeric organization
of mPGES-1.
Together with other studies published to date, mPGES-1 has been verified
biologically as a drug target and the next stop in this validation
process requires specific inhibitors to be tested in animal disease
models
Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines
Gastrointestinal carcinomas synthesize elevated levels of prostaglandin E(2) (PGE(2)), which has been mechanistically linked to carcinogenesis. Recently, microsomal prostaglandin E synthase-1 (mPGES-1) was cloned, which seems to be inducible and linked to cyclooxygenase-2 (Cox-2) in the biosynthesis of PGE(2). We examined expression of mPGES-1 in intestinal type gastric adenocarcinomas and in gastric cancer cell lines. The transcript for mPGES-1 was elevated in 57% (4/7) of gastric carcinomas as detected by Northern blot analysis. Moderate to strong mPGES-1 immunoreactivity was observed in 56% (5/9) of the carcinomas as detected by immunohistochemistry. Furthermore, mPGES-1 mRNA, protein and microsomal PGES activity were detected in gastric adenocarcinoma cell lines that originated from intestinal type tumors (MKN-7 and MKN-28). In contrast to Cox-2, however, expression of mPGES-1 mRNA or protein were not induced by phorbol 12-myristate 13-acetate (PMA) or interleukin-1beta (IL-1beta) in any of the gastric cancer cell lines tested (MKN-1, -7, -28, -45 and -74). Two gastric cancer cell lines (MKN-45 and MKN-74) did not express mPGES-1 and lacked microsomal PGES activity, but were still able to synthesize PGE(2). Because all gastric cell lines expressed cPGES as detected by immunoblotting, it is possible that Cox-2 can interact with cPGES or with some other yet unidentified PGES in gastric cancer cells. Furthermore, our data show that regulatory mechanisms that drive expression of mPGES-1 and Cox-2 dissociate in gastric cancer cell line